Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Kinnevik's Total Shares Fall to 280,808,985, Voting Rights to 584,585,220

Kinnevik's Total Shares Fall to 280,808,985, Voting Rights to 584,585,220

BitgetBitget2026/10/30 07:38
  • Kinnevik's total issued shares fell to 280,808,985 as of October 30, 2026; total voting rights declined to 584,585,220.
  • The decrease reflects redemption of all 396,523 Class C 2021 incentive shares and 396,523 Class D 2021 incentive shares.
  • Applicable performance conditions were not met during October 1, 2021–September 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kinnevik AB published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12